| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9953077 | Value in Health Regional Issues | 2018 | 7 Pages |
Abstract
The direct medicine treatment cost of RA in the South African private health sector is driven by the high volume of DMARDs and the high mean costs of biologics, particularly adalimumab.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Nericke BPharm, Martie PhD, Rianda PhD, Adele MHPE, Johanita PhD,